LG-2527

Chemical compound
LG-2527
Clinical data
Drug classProgestin; Progestogen

LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer , but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]

References

  1. ^ a b "LG 2527 - AdisInsight". adisinsight.springer.com.


  • v
  • t
  • e
Progesterone receptor modulators
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
See also
Receptor/signaling modulators
Progestogens and antiprogestogens
Androgen receptor modulators
Estrogen receptor modulators
List of progestogens


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e